Xiaoming Fei1,2, Fang Lei1, Haifeng Zhang3, Hua Lu3, Yan Zhu1, Yu Tang4. 1. Affiliated Hospital of Jiangsu University, Jiangsu University, 438# Jiefang Road, 212001, Zhenjiang, Jiangsu Province, People's Republic of China. 2. Hematology Research Institute, Jiangsu University, 438# Jiefang Road, Zhenjiang, 212001, Jiangsu Province, People's Republic of China. 3. First Affiliated Hospital of Nanjing Medical University, 140# Hanzhong Road, Nanjing, 210029, Jiangsu Province, People's Republic of China. 4. Affiliated Hospital of Jiangsu University, Jiangsu University, 438# Jiefang Road, 212001, Zhenjiang, Jiangsu Province, People's Republic of China. feixiaomingujs@aliyun.com.
Abstract
PURPOSE: The purpose of this study was to develop a mathematical model that predicts the definite adverse events following chemotherapy in patients with hematological malignancies (HMs). METHODS: This is a retrospective cohort study including 1157 cases with HMs. Firstly, we screened and verified the independent risk factors associated with post-chemotherapy adverse events by both univariate and multivariate logistic regression analysis using 70 % of randomly selected cases (training set). Secondly, we proposed a mathematical model based on those selected factors. The calibration and discrimination of the model were assessed by Hosmer-Lemeshow (H-L) test and area under the receiver operating characteristic (ROC) curve, respectively. Lastly, the predicative power of this model was further tested in the remaining 30 % of cases (validation set). RESULTS: Our statistical analysis indicated that liver dysfunction (OR = 2.164), active infection (OR = 3.619), coagulation abnormalities (OR = 4.614), intensity of chemotherapy (OR = 10.001), acute leukemia (OR = 2.185), and obesity (OR = 1.604) were independent risk factors for post-chemotherapy adverse events in HM patients (all P < 0.05). Based on the verified risk factors, a predictive model was proposed. This model had good discrimination and calibration. When 0.648 was selected as the cutoff point, the sensitivity and specificity of this predictive model in validation sets was 72.7 and 87.4 %, respectively. Furthermore, this proposed model's positive predictive value, negative predictive value, and consistency rate were 87.3, 73.0 and 80.0 %, respectively. CONCLUSIONS: Our study indicated that this six risk factor-based mathematical model is accurate and sufficient enough to predict definite post-chemotherapy adverse events in a HM patient and it may aid clinicians to optimize treatment for a HM patient.
PURPOSE: The purpose of this study was to develop a mathematical model that predicts the definite adverse events following chemotherapy in patients with hematological malignancies (HMs). METHODS: This is a retrospective cohort study including 1157 cases with HMs. Firstly, we screened and verified the independent risk factors associated with post-chemotherapy adverse events by both univariate and multivariate logistic regression analysis using 70 % of randomly selected cases (training set). Secondly, we proposed a mathematical model based on those selected factors. The calibration and discrimination of the model were assessed by Hosmer-Lemeshow (H-L) test and area under the receiver operating characteristic (ROC) curve, respectively. Lastly, the predicative power of this model was further tested in the remaining 30 % of cases (validation set). RESULTS: Our statistical analysis indicated that liver dysfunction (OR = 2.164), active infection (OR = 3.619), coagulation abnormalities (OR = 4.614), intensity of chemotherapy (OR = 10.001), acute leukemia (OR = 2.185), and obesity (OR = 1.604) were independent risk factors for post-chemotherapy adverse events in HM patients (all P < 0.05). Based on the verified risk factors, a predictive model was proposed. This model had good discrimination and calibration. When 0.648 was selected as the cutoff point, the sensitivity and specificity of this predictive model in validation sets was 72.7 and 87.4 %, respectively. Furthermore, this proposed model's positive predictive value, negative predictive value, and consistency rate were 87.3, 73.0 and 80.0 %, respectively. CONCLUSIONS: Our study indicated that this six risk factor-based mathematical model is accurate and sufficient enough to predict definite post-chemotherapy adverse events in a HM patient and it may aid clinicians to optimize treatment for a HM patient.
Authors: Arti Hurria; Kayo Togawa; Supriya G Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Stuart M Lichtman; Ajeet Gajra; Smita Bhatia; Vani Katheria; Shira Klapper; Kurt Hansen; Rupal Ramani; Mark Lachs; F Lennie Wong; William P Tew Journal: J Clin Oncol Date: 2011-08-01 Impact factor: 44.544
Authors: Parag Mahale; Dimitrios P Kontoyiannis; Roy F Chemaly; Ying Jiang; Jessica P Hwang; Marta Davila; Harrys A Torres Journal: J Hepatol Date: 2012-08-04 Impact factor: 25.083
Authors: Massimo Marignani; Elia Gigante; Paola Begini; Alfredo Marzano; Michela di Fonzo; Ilaria Deli; Sara Gallina; Maria Christina Cox; Gianfranco Delle Fave Journal: World J Gastrointest Oncol Date: 2012-03-15
Authors: Theis H Terwey; Philipp G Hemmati; Peter Martus; Ekkehart Dietz; Lam G Vuong; Gero Massenkeil; Bernd Dörken; Renate Arnold Journal: Haematologica Date: 2009-12-08 Impact factor: 9.941
Authors: Corinna Hahn-Ast; Axel Glasmacher; Sara Mückter; Andrea Schmitz; Anja Kraemer; Günter Marklein; Peter Brossart; Marie von Lilienfeld-Toal Journal: J Antimicrob Chemother Date: 2010-01-27 Impact factor: 5.790